Rugo HS, Harbeck N, Hortobagyi GN, O'Shaughnessy J, et al. Safety and treatment duration of ribociclib + nonsteroidal aromatase inhibitor in HR+/HER2- early breast cancer: a phase 3 randomized controlled trial (NATALEE). Breast Cancer Res 2026;28:186.
PMID: 42968162